<DOC>
	<DOCNO>NCT00187551</DOCNO>
	<brief_summary>The goal study examine whether enfuvirtide ( T20 , Fuzeon ) continue anti-HIV activity patient experience incomplete virologic response enfuvirtide-based regimen .</brief_summary>
	<brief_title>Pilot Study Evaluating Interruption Enfuvirtide ( Fuzeon , T20 ) Patients With Enfuvirtide Resistance</brief_title>
	<detailed_description>Some patient achieve undetectable HIV viral load enfuvirtide ( T20 , Fuzeon ) base antiretroviral regimen . As consequence , enfuvirtide resistant virus emerge . It yet know enfuvirtide continue virologic immunologic benefit drug-resistant variant emerges . Interrupting enfuvirtide may reduce accumulation enfuvirtide mutation may allow potent response enfuvirtide future regimen . Subjects must evidence viral replication ( HIV RNA &gt; 1,000 copies/ml two consecutive measurement ) stable antiretroviral regimen contain enfuvirtide . Patients interrupt enfuvirtide continue antiretroviral agent . Subjects see weekly four week , every two week additional 8 week , every four week week 48 . Plasma HIV RNA level CD4+/CD8+ T cell count measure real time visit , provide refer primary care physician . Subjects allow resume enfuvirtide time course study . Subjects encourage resume enfuvirtide ( without modify background regimen ) plasma HIV RNA level increase &gt; 0.5 log two consecutive occasion . Subjects see every four week 24 week enfuvirtide resume . Plasma collect visit HIV RNA store retrospective genotype/phenotype evaluation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Currently receive continuous enfuvirtidebased antiretroviral therapy . Documentation recent plasma HIV RNA level great low limit detection ( measure within precede 4 week ) Screening plasma HIV1 RNA level &gt; 1000 copies/mL . Negative serum pregnancy test ( woman childbearing potential ) document within 14day period prior study entry . Subjects must able give write informed consent agree abide requirement study . Unstable HIV disease status interrupt antiretroviral therapy pose significant shortterm risk disease progression ( determine study investigator refer primary care provider ) . Female subject pregnant , breastfeeding , plan become pregnant study . Active hepatitis C infection require treatment interferonbased regimen . Evidence active , untreated opportunistic infection unexplained temperature &gt; 38.5Â°C seven consecutive day , within 30 day prior first screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>enfuvirtide</keyword>
	<keyword>T20</keyword>
	<keyword>Fuzeon</keyword>
	<keyword>Treatment</keyword>
	<keyword>Interruption</keyword>
	<keyword>Resistance</keyword>
	<keyword>HIV Drug Resistance</keyword>
	<keyword>Antiretroviral Agents</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>Drug Resistance , Multiple</keyword>
	<keyword>Human Immunodeficiency virus</keyword>
</DOC>